Preclinical and clinical results with the natural marine product ET-743.
about
Novel Marine Compounds: Anticancer or Genotoxic?Adding pharmacogenomics to the development of new marine-derived anticancer agentsMarine Invertebrate Metabolites with Anticancer Activities: Solutions to the "Supply Problem"Cancer wars: natural products strike backEfficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.Role of trabectedin in the treatment of soft tissue sarcomaTranscription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complexEmerging treatments for soft tissue sarcoma of adults.A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsRecent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsA phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerEfficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.Trabectedin for the treatment of soft tissue sarcomas.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Mode of action of trabectedin in myxoid liposarcomas.Olaratumab for the treatment of advanced soft tissue sarcoma.
P2860
Q24804433-EECBA0E0-7D50-4184-A194-D4612657BF71Q25254985-36ABA5EC-CAAC-4D12-A31D-EA92BE229492Q26746924-D7B6792C-D90F-46C8-9A6F-EBEB6E754680Q26850074-BFB3BBB1-4DF4-4968-8DEF-2CA59A5093F9Q33442984-0DBCE5A3-326D-4759-AF06-CB01DF5D85EAQ33916011-F3038400-123E-4717-9A13-B2CE5FDC2E0AQ34594349-8BE9F15A-23A2-4B6D-9D96-709DA49467DFQ35967402-2E8B473F-176F-445A-A6AE-DCDE248C5B68Q36233516-F4157D20-F22F-461A-AEBC-51EE4EBDD104Q36273796-C2F9310D-2B2F-44C0-A6CF-32D9E101DF86Q36614276-9A0B8195-9F9A-4E2A-8AC0-B8431052C357Q37350801-D856B480-7888-4CE4-A91A-9E014B1FF785Q37854494-2141E59E-4225-4E53-B149-AD433CCC4719Q37969213-59E4C5E6-4C5D-4F49-9A6F-EEB7D7C02381Q38872192-F9277C77-419A-4A9C-99A6-A092894A5DD5Q41105379-8B410A86-973B-490E-BA4E-285426AA0485Q45346605-6369B151-C1D9-47B3-961A-85BAF6C96797Q47729241-D21793AF-B595-462F-9994-438344CA437F
P2860
Preclinical and clinical results with the natural marine product ET-743.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Preclinical and clinical results with the natural marine product ET-743.
@ast
Preclinical and clinical results with the natural marine product ET-743.
@en
Preclinical and clinical results with the natural marine product ET-743.
@nl
type
label
Preclinical and clinical results with the natural marine product ET-743.
@ast
Preclinical and clinical results with the natural marine product ET-743.
@en
Preclinical and clinical results with the natural marine product ET-743.
@nl
prefLabel
Preclinical and clinical results with the natural marine product ET-743.
@ast
Preclinical and clinical results with the natural marine product ET-743.
@en
Preclinical and clinical results with the natural marine product ET-743.
@nl
P2860
P1476
Preclinical and clinical results with the natural marine product ET-743.
@en
P2093
José Jimeno
Maurizio D'Incalci
P2860
P304
P356
10.1517/13543784.12.11.1843
P407
P577
2003-11-01T00:00:00Z